Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
What is your approach to biologic therapy in older adults (80+) with RA and CKD?
Related Questions
How do you approach management of RA in patients who have developed anti-drug antibodies to infliximab, especially if use of methotrexate is contraindicated and patients have tried and failed several other biologics?
Are there any recommendations for restarting JAKi after a provoked DVT?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
How do you help patients understand the difference between prolonged morning stiffness and pain?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
